Canadian clinic launches 3-year study on medical cannabis

The Canadian medical cannabis dispensary Health Cannabis has launched a pivotal real-world evidence study to evaluate the efficacy of various medical cannabis treatments.

With a recruitment target of 3,000 patients, this three-year project represents a major step forward in the exploration of cannabis-based therapies. The study is set to examine different cannabis treatment formats and different cannabinoid formulations, focusing on existing and latest methods.

Bridging the knowledge gap on medical cannabis

Although the medical cannabis has been legally available in Canada since 2001, many questions remain as to its full therapeutic potential.

Despite nearly 25 years of legalization, clinicians and researchers are still discovering the complexities surrounding cannabis for conditions such as chronic pain, epilepsy, spasticity, anxiety, depression and sleep disorders.

The Dr Michael Dworkind, medical director and co-founder of Santé Cannabis, underlines the importance of this study: «Many questions remain unanswered about the therapeutic potential of cannabis in conditions such as chronic pain, epilepsy, spasticity, sleep disorders, anxiety and depression. This study is an essential step in addressing patients» needs in the evolving cannabis landscape".

The study aims to fill this gap by examining the outcomes of patients using new cannabis products, such as capsules, tablets, sublingual formats and innovative formulations in cannabinoids, including the CBN and the CBG, Unlike traditional treatments, which focus on THC and CBD.

The safety and efficacy of these new treatments, combined with traditional cannabis-based therapies, will be evaluated in real-life situations.

Collaboration and industry support

The study is supported by major industry players, including Tilray, Aurora, and Vectura Fertin Pharma, a Singapore-based company renowned for its work on cannabinoids. These partnerships provide both financial backing and expertise to support the research initiative. However, Santé Cannabis is still looking for additional collaborators to broaden the scope and impact of the study.

Since its creation in 2014, Health Cannabis provided care and support to more than 20,000 patients and was the first contract research organization (ORC) on the Cannabis independently accredited in Canada. Over the years, the clinic has conducted numerous clinical trials and observational studies, supported by its four cannabis research licenses.

In addition to cannabis research, Santé Cannabis has launched a program of psychedelic-assisted therapy in 2024. This initiative aims to improve access to legal psychedelic treatments, strengthen research opportunities and develop new models of care. Through this program, Santé Cannabis aims to push back the boundaries of medical treatment and offer alternative therapeutic solutions.

The importance of hard data

One of the key elements of the study is its focus on real-life data. According to the clinic, this method will enable the efficacy of treatments to be assessed in an everyday context, as opposed to the controlled environment of clinical trials. This approach provides valuable information on how medical cannabis products work under normal conditions, which in turn will help clinicians make more informed decisions about treatment plans.

According to the Dr Lorne Wiseblatt, family physician and palliative care At Santé Cannabis, the study is essential to providing patients with safe and effective treatment options: «As clinicians, we must fulfill our responsibility to support our patients with safe and effective treatment options. By integrating hard data, the study will provide a better understanding of the impact of different cannabis treatments on patients over time.»

A growing need for medical cannabis research

According to Santé Cannabis, as of March 2024, there were over 180,000 patients registered with federally-licensed sellers in Canada. With the average authorized amount being 2.4 grams per day, the demand for reliable and effective cannabis-based treatments continues to grow. The results of the study could play a crucial role in defining the future of medical cannabis, not only in Canada, but worldwide.

This research comes at a pivotal time in the evolution of cannabis-based treatments, as more and more patients turn to cannabis to alleviate their chronic illnesses. The results of this study will not only help clinicians better understand how to optimize cannabis treatment plans, but will also contribute to the wider acceptance and integration of medical cannabis into healthcare systems worldwide.